Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phrase “mucopolysaccharide polymers in the respiratory tract” is imprecise, as it conflates several molecular classes. Correctly, the principal polymeric components of airway mucus are **mucin glycoproteins**, notably Mucin 5AC (MUC5AC) and Mucin 5B (MUC5B), which are high molecular weight, heavily O-glycosylated proteins secreted by the airway epithelium[1][2]. These mucins polymerize to form a gel, providing a protective barrier that traps inhaled particles and pathogens, facilitates mucociliary clearance, regulates hydration, and modulates the immune response[1][2]. Abnormalities in mucin production, structure, or clearance are implicated in diseases such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD)[1][2]. Mucolytic treatments (e.g., N-acetylcysteine) reduce mucus viscosity by disrupting mucin disulfide cross-links, thereby improving clearance[1]. **Note:** - “Mucopolysaccharide polymers” may refer to glycosaminoglycans (GAGs), which are distinct from mucins but also present in lung extracellular matrix and airway secretions[2][4]. However, the main therapeutic and physiological interest in mucus comes from mucin glycoproteins, not GAGs. - This entry is marked as "is_incorrect: true" because "mucopolysaccharide polymers in the respiratory tract" is not a standard molecular target but rather a descriptive term encompassing multiple biopolymers; the canonical molecular targets are MUC5AC and MUC5B, which should be used for structured analyses[1][2]. If you seek information on glycosaminoglycans (GAGs) instead (e.g., hyaluronic acid, heparan sulfate), further clarification is required, as those are a separate molecular class relevant in lung ECM biology and disease, but not the main polymeric barrier in the airway mucus gel[2][4].
Mucolytics: cleavage of disulfide bonds or DNA within mucus to decrease viscosity. Hydrators: draw water into airway lumen to improve mucus clearance.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucin biopolymer (main types: Mucin 5AC, Mucin 5B) (MUC5AC, MUC5B).